Skip to main content
    T

    Taysha Gene Therapies Inc (TSHA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.00
    -0.06 (-1.48%)

    Market Cap: $1.32B

    Last updated: Nov 17, 2026 at 4:11 PM ET

    Taysha Gene Therapies Inc (TSHA) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Taysha Gene Therapies (TSHA) trades at 296.2x sales and 4.6x book value. Its P/B of 4.6x is below its 5-year median of 5.5x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales296.2x
    Price to book4.6x
    PEGN/A
    FCF yield-8.7%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B4.6x5.5xN/A
    Medians of month-end values through Oct 2026: 51 months (5-year).

    Valuation History

    Over the 4 of the 6 year ends shown that have a P/S, its P/S ranged from 10.5x in 2023 to 169.9x in 2025. 2025 was the highest of those years.

    Year endPriceP/SP/B
    2025$5.50169.9x7.1x
    2024$1.7348.0x5.0x
    2023$1.7710.5x4.4x
    2022$2.2650.9x134.3x
    2021$11.65N/A4.7x
    2020$26.54N/A4.0x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About TSHA

    What is TSHA's price to sales ratio?

    Taysha Gene Therapies has a price to sales ratio of 296.2x.